Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 15/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20653063 | 0.95 | P2RX3 (0.43) | P2RX3ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL20656216 | 0.94 | P2RX3 (0.40) | P2RX3ALDH1A1MAPTSMN1; SMN2HIF1A | |
| SCHEMBL20653068 | 0.91 | P2RX3 (0.43) | P2RX3ALDH1A1MAPTSMN1; SMN2HIF1A | |
| SCHEMBL20652933 | 0.91 | P2RX3 (0.41) | P2RX3ALDH1A1MAPTSMN1; SMN2HIF1A | |
| SCHEMBL20653053 | 0.90 | P2RX3 (0.44) | P2RX3ALDH1A1MAPTSMN1; SMN2HIF1A | |
| SCHEMBL20652796 | 0.90 | P2RX3 (0.42) | P2RX3ALDH1A1MAPTSMN1; SMN2HIF1A | |
| SCHEMBL20652979 | 0.88 | P2RX3 (0.42) | P2RX3ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL24095610 | 0.88 | P2RX3 (0.42) | P2RX3ALDH1A1MAPTSMN1; SMN2HIF1A | |
| SCHEMBL20652948 | 0.86 | ADORA3 (0.41) | P2RX3ALDH1A1MAPTSMN1; SMN2HIF1A | |
| SCHEMBL20652794 | 0.86 | P2RX3 (0.45) | P2RX3ALDH1A1MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3652176-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2021-12-15 | — | — | EP | disclosed |
| US-10329292-B2 | Substituted xanthine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20190016722-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329292-B2 | Substituted xanthine derivatives | TRPC5, TRPV1, TRPC4 | P2RX3 21/4885ALDH1A1 1347/4885MAPT 1268/4885 |
| US-20190016722-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPV1 | P2RX3 19/4885ALDH1A1 1488/4885MAPT 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.